These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 10465169)

  • 1. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
    Davies L; Angus RM; Calverley PM
    Lancet; 1999 Aug; 354(9177):456-60. PubMed ID: 10465169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
    van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
    Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
    Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Trials; 2015 Jun; 16():267. PubMed ID: 26058585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
    Duffy N; Walker P; Diamantea F; Calverley PM; Davies L
    Thorax; 2005 Sep; 60(9):713-7. PubMed ID: 15939732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
    Ramakrishnan S; Jeffers H; Langford-Wiley B; Davies J; Thulborn SJ; Mahdi M; A'Court C; Binnian I; Bright S; Cartwright S; Glover V; Law A; Fox R; Jones A; Davies C; Copping D; Russell RE; Bafadhel M
    Lancet Respir Med; 2024 Jan; 12(1):67-77. PubMed ID: 37924830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease.
    Morice AH; Morris D; Lawson-Matthew P
    Clin Pharmacol Ther; 1996 Dec; 60(6):675-8. PubMed ID: 8988070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
    Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
    Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.
    Paggiaro PL; Dahle R; Bakran I; Frith L; Hollingworth K; Efthimiou J
    Lancet; 1998 Mar; 351(9105):773-80. PubMed ID: 9519948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.
    Vestbo J; Sørensen T; Lange P; Brix A; Torre P; Viskum K
    Lancet; 1999 May; 353(9167):1819-23. PubMed ID: 10359405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial.
    Devereux G; Cotton S; Nath M; McMeekin N; Campbell K; Chaudhuri R; Choudhury G; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; MacLennan G; Morice A; Norrie J; Price D; Short P; Vestbo J; Walker P; Wedzicha J; Wilson A; Wu O; Lipworth BJ
    JAMA; 2024 Aug; 332(6):462-470. PubMed ID: 38762800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
    Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.
    Sivapalan P; Lapperre TS; Janner J; Laub RR; Moberg M; Bech CS; Eklöf J; Holm FS; Armbruster K; Sivapalan P; Mosbech C; Ali AKM; Seersholm N; Wilcke JT; Brøndum E; Sonne TP; Rønholt F; Andreassen HF; Ulrik CS; Vestbo J; Jensen JS
    Lancet Respir Med; 2019 Aug; 7(8):699-709. PubMed ID: 31122894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
    Walters JA; Wang W; Morley C; Soltani A; Wood-Baker R
    Cochrane Database Syst Rev; 2011 Oct; (10):CD006897. PubMed ID: 21975757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
    Brightling CE; Monteiro W; Ward R; Parker D; Morgan MD; Wardlaw AJ; Pavord ID
    Lancet; 2000 Oct; 356(9240):1480-5. PubMed ID: 11081531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease.
    Bourbeau J; Rouleau MY; Boucher S
    Thorax; 1998 Jun; 53(6):477-82. PubMed ID: 9713447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease.
    Davies L; Nisar M; Pearson MG; Costello RW; Earis JE; Calverley PM
    QJM; 1999 Jul; 92(7):395-400. PubMed ID: 10627889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.